SAN FRANCISCO (Thomson Financial) - Genitope Corp. said late Thursday its
pivotal Phase III clinical trial examining the use of MyVax personalized
immunotherapy in previously untreated follicular B-cell non-Hodgkin's lymphoma
patients did not meet its primary endpoint.
There was no statistically significant difference in the progression-free
survival of patients receiving MyVax compared to patients receiving the control
substance, the Fremont, Calif.-based company said.
However, the company said analysis of a pre-specified endpoint in the MyVax
arm showed a highly statistically significant difference in progression-free
survival between patients who mounted a positive immune response to the
tumor-specific target and those who did not.
Shares of Genitope plunged 50% in after-hours trade after closing the
regular session at $2.59.
Gabriel Madway
gm
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|